3 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow SARS-CoV2 Infection: new trials by email Literature Review of SARS-CoV2 Infection trials Research Report on SARS-CoV2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
| Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 Candesartan Cilexetil, Repagermanium, Candesartan Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 | Terminated | University of Sydney | 49 | 2022-01-07 | 2023-09-15 |
| Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection | Phase 2 | Terminated | Leidos Life Sciences | 4 | 2021-12-29 | 2024-07-09 |
COVID-19 (3) · Coronavirus Infections (1)
Coronaviridae Infections (3) · Infections (3) · Lung Diseases (3) · Nidovirales Infections (3) · Pneumonia (3) · Pneumonia, Viral (3) · RNA Virus Infections (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Virus Diseases (3) · Coronavirus Infections (2)
Celecoxib (1) · Famotidine (1) · candesartan cilexetil (1) · fostamatinib (1) · propagermanium (1)
Leidos Life Sciences (1) · NEAT ID Foundation (1) · University of Sydney (1)
Brazil (1) · Germany (1) · India (1) · Italy (1) · South Africa (1) · Spain (1) · United States (1)
Anton Pozniak, Prof (1) · Brian A Roberts, MS, PMP (1) · Meg Jardine (1) · Vivekanand Jha (1)